Case MC058YP

In the Claims

1. Cancel.
2. Cancel.
3. Cancel.
4. Cancel.
5. Cancel.
6. Cancel.
7. Cancel.
8. Cancel.
9. Cancel.
10. Cancel.
11. Cancel.
12. Cancel.
13. Cancel.
14. Cancel.
15. Cancel.
16. Cancel.

17(Original) A compound of structural formula I:



I

or a pharmaceutically acceptable salt, enantiomer, diastereomer, pro drug or mixture thereof, wherein

X is $(CH_2)_n$, O or S;

Y represents $(C(R^b)_2)_n$, triple bond,  ;

Ar_2 independently represent $(CH_2)_mC_{6-10}$aryl, $(CH_2)_mC_{5-10}$heteroaryl, $(CH_2)_mC_{3-10}$ heterocycloalkyl, $(CH_2)_mC_{3-8}$ cycloalkyl said cycloalkyl, heterocycloalkyl, aryl or heteroaryl unsubstituted or substituted with 1-3 groups of R_a;

R_a represents C_{1-6} alkoxy, C_{1-6} alkyl, CF_3, nitro, amino, cyano, C_{1-6} alkylamino, or halogen;

R^b independently represents H, halogen, C_{1-6} alkyl, C_{3-6} cylcoalkyl or

--- represents a double or single bond;

n represents 0-4; and

m represents 0-8.

18(Original). The compound according to claim 17 wherein X and Y are $(CH_2)_n$, --- represents a double bond; and Ar_2 is phenyl.

19(Original). The compound according to claim 18 wherein X is $(CH_2)_n$ and n is 1 and Y is $(CH_2)_n$ and n is 3.

20 Cancel.

21(Currently Amended) A pharmaceutical composition for treating ocular hypertension or glaucoma comprising a therapeutically effective amount of a compound of formula I of claim 17 ~~as defined in any one of claims 1 to 10,~~ or a pharmaceutically acceptable salt, enantiomer, diasteromer, prodrug, or mixture thereof, in association with a pharmaceutically acceptable carrier.

22 (Currently Amended) A composition according to claim 21 in a form for topical administration as a solution or suspension ~~and further comprising a second active ingredient as defined in claim 12 or 13~~.

23 Cancel.

24 Cancel.

25 Cancel.

26 Cancel.

27 (New) A composition according to claim 22 wherein a second active ingredient belonging to the group consisting of: b-adrenergic blocking agent, parasympatho-memetic agent, sympathomimetic agent, carbonic anhydrase inhibitor, Maxi-K channel blocker, a prostaglandin, hypotensive lipid, neuroprotectant, and 5-HT2 receptor agonist is added.

28 (New) A composition according to claim 27 wherein the β-adrenergic blocking agent is timolol, betaxolol, levobetaxolol, carteolol, or levobunolol; the parasympathomimetic agent is pilocarpine; the sympathomimetic agent is epinephrine, brimonidine, iopidine, clonidine, or para-aminoclonidine, the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or brinzolamide; the prostaglandin is latanoprost, travaprost, unoprostone, rescula, or S1033, the hypotensive lipid is lumigan, the neuroprotectant is eliprodil, R-eliprodil or memantine; and the 5-HT2 receptor agonist is 1-(2-aminopropyl)-3-methyl-1H-imdazol-6-ol fumarate or 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine.